Andrew Thorp, MD
Cardiovascular Disease · Lincoln, RINPI 1013367515
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Medtronic at 41.3% of the total. Reporting peaked in 2021 at $3,448 and has fallen 59.1% since, to $1,411 in 2025. Among cardiovascular disease clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $56.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$3K
- Novartis$340
- E.r. Squibb & Sons, L.L.C.$206
- Abiomed$178
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$157
- plus $1K from 15 others
What the payments were for
- Travel & lodging$2,95037%
- Food & beverage$4,25153%
- Education$77610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 32 | $3,297 |
| Abbott | 29 | $2,588 |
| Novartis | 18 | $340 |
| E.r. Squibb & Sons, L.L.C. | 10 | $206 |
| Abiomed | 3 | $178 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $157 |
| Novo Nordisk | 8 | $153 |
| Amgen | 6 | $152 |
| Edwards Lifesciences | 1 | $125 |
| Terumo Medical Corporation | 1 | $123 |
| Pfizer | 5 | $118 |
| Cathworks, Inc. | 1 | $84 |
| Boehringer Ingelheim | 4 | $72 |
| Bayer | 3 | $72 |
| Scpharmaceuticals Inc. | 4 | $67 |
| AstraZeneca | 3 | $64 |
| Penumbra, Inc. | 1 | $63 |
| Shockwave Medical, Inc | 1 | $47 |
| Acist Medical Systems, Inc. | 1 | $27 |
| Boston Scientific | 1 | $25 |
| Merck | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$2,141
- Ensite Cardiac Mapping System$1,314
- EnSite Precision Cardiac Mapping System$153
- AVEIR$123
- ANGIO-SEAL$123
- HawkOne$122
- Impella$114
- COREVALVE EVOLUT R$107
How this compares
$7,977 in reported general payments places this provider in the 90th percentile of 86 cardiovascular disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $71,504 |
| EntrestoSacubitril/Valsartan | 29 | $45,217 |
| FarxigaDapagliflozin Propanediol | 23 | $30,014 |
| BrilintaTicagrelor | 22 | $17,841 |
| Fenofibrate | 13 | $2,547 |
| Atorvastatin Calcium | 170 | $1,337 |
| Metoprolol Succinate | 80 | $1,056 |
| Amlodipine Besylate | 87 | $649 |
| Valsartan | 12 | $540 |
| Losartan Potassium | 58 | $398 |
| ClopidogrelClopidogrel Bisulfate | 34 | $356 |
| Metoprolol Tartrate | 41 | $342 |
| Rosuvastatin Calcium | 28 | $330 |
| Furosemide | 57 | $176 |
| Carvedilol | 29 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $118 | $71,50456 claims |
| AstraZenecaFarxiga, Brilinta | $64 | $47,85545 claims |
| NovartisEntresto | $340 | $45,21729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 86 cardiovascular disease providers in Rhode Island.
Other cardiovascular disease in Lincoln
- Hoshang FarhadLincoln$3K
- Joseph MazzaLincoln$189
- Ibrahim ElgabryWoonsocket$72K
- Ara SadaniantzProvidence$27K
- George BourganosWoonsocket$16K
- Edward ThomasWarwick$15K
- John CavaProvidence$12K
- Jeremy LumProvidence$10K
- Franklin SchneiderProvidence$8K
- Andrew HordesPawtucket$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.